NYSEMKT:PHGE BiomX (PHGE) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free PHGE Stock Alerts $0.42 +0.07 (+20.11%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.4950-Day Range$0.27▼$0.4852-Week Range N/AVolume1.40 million shsAverage Volume68,601 shsMarket Capitalization$29.18 millionP/E RatioN/ADividend YieldN/APrice Target$2.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesOwnershipSEC Filings BiomX MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside438.3% Upside$2.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.25Based on 8 Articles This WeekInsider TradingSelling Shares$9,251 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has only been the subject of 2 research reports in the past 90 days.Read more about BiomX's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PHGE. Previous Next 0.0 Dividend Strength Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHGE. Previous Next 1.0 News and Social Media Coverage News SentimentBiomX has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BiomX this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 2 people have added BiomX to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,251.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About BiomX Stock (NYSEMKT:PHGE)BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More PHGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGE Stock News HeadlinesMay 30 at 4:50 PM | globenewswire.comBiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsMay 30 at 7:00 AM | globenewswire.comBiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024May 29 at 3:16 AM | americanbankingnews.comBiomX (NYSEMKT:PHGE) Receives New Coverage from Analysts at LaidlawMay 25, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for BiomX Inc.'s Q2 2024 Earnings (NYSEMKT:PHGE)May 22, 2024 | americanbankingnews.comBiomX (NYSEMKT:PHGE) Earns "Buy" Rating from HC WainwrightMay 21, 2024 | globenewswire.comBiomX Reports First Quarter 2024 Financial Results and Provides Business and Program UpdatesMay 15, 2024 | globenewswire.comBiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024May 14, 2024 | finance.yahoo.comBiomX to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 25, 2024 | investing.comBiomx Inc (PHGE_u)April 23, 2024 | globenewswire.comBiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)April 19, 2024 | investing.comBiomX expands board with new director and audit chairApril 18, 2024 | globenewswire.comBiomX Announces the Appointment of Susan Blum to its Board of DirectorsApril 6, 2024 | uk.investing.comBiomX receives going concern note from auditorsApril 4, 2024 | globenewswire.comBiomX Announces Compliance with NYSE Guidelines on Audit Opinion DisclosureApril 3, 2024 | msn.comU.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge HigherApril 3, 2024 | globenewswire.comBiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | globenewswire.comBiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024March 18, 2024 | globenewswire.comBiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million FinancingMarch 7, 2024 | markets.businessinsider.comBiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical TrialsMarch 7, 2024 | markets.businessinsider.comBiomX Acquisition and Clinical Trial Successes Prompt Buy Rating by Analyst Michael HigginsMarch 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage TherapeuticsMarch 6, 2024 | msn.comWhy BiomX Stock Is Surging TodayMarch 6, 2024 | investorplace.comWhy Is BiomX (PHGE) Stock Up 147% Today?March 6, 2024 | globenewswire.comBiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million FinancingJanuary 29, 2024 | msn.comNanoViricides reports positive safety results for COVID drug candidateSee More Headlines Company Calendar Last Earnings5/15/2023Today5/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEMKT:PHGE CUSIPN/A CIK1739174 Webwww.biomx.com Phone972 7 23942377FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$2.50 Low Stock Price Target$2.00 Potential Upside/Downside+542.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.82% Return on Assets-56.50% Debt Debt-to-Equity Ratio0.51 Current Ratio2.84 Quick Ratio2.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.50Miscellaneous Outstanding Shares69,806,000Free Float44,044,000Market Cap$24.43 million OptionableNot Optionable Beta1.31 Key ExecutivesMr. Jonathan Eitan Solomon MBA (Age 47)CEO & Director Comp: $714.37kDr. Merav Bassan Ph.D. (Age 58)Chief Development Officer Comp: $437.71kMs. Marina Wolfson CPA (Age 40)CFO & Secretary (Leave of Absence) Comp: $337.51kProf. Rotem Sorek Ph.D.Scientific FounderDr. Eran Elinav M.D.Ph.D., Scientific FounderDr. Timothy K. Lu M.D. (Age 43)Ph.D., Scientific Founder Mr. Avraham Gabay (Age 38)Interim Chief Financial Officer Ms. Inbal Benjamini-ElranC.H.R.OMr. Assaf Oron (Age 50)Chief Business Officer Comp: $352.04kMore ExecutivesKey CompetitorsNervGen PharmaOTCMKTS:NGENFAmpliphi BiosciencesNYSEAMERICAN:APHBMural OncologyNASDAQ:MURALianBioNASDAQ:LIANEnlivex TherapeuticsNASDAQ:ENLVView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 10,817,327 shares on 5/17/2024Ownership: 19.590%Israel Biofund Gp Limi OrbimedSold 24,344 sharesTotal: $9,250.72 ($0.38/share)Johnson & JohnsonSold 210,201 shares on 5/10/2024Ownership: 3.483%View All Insider TransactionsView All Institutional Transactions PHGE Stock Analysis - Frequently Asked Questions Should I buy or sell BiomX stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks. What is BiomX's stock price target for 2024? 2 brokerages have issued 12-month price objectives for BiomX's stock. Their PHGE share price targets range from $2.00 to $2.50. On average, they anticipate the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 438.3% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts. How have PHGE shares performed in 2024? BiomX's stock was trading at $0.28 at the beginning of the year. Since then, PHGE shares have increased by 49.3% and is now trading at $0.4180. View the best growth stocks for 2024 here. How were BiomX's earnings last quarter? BiomX Inc. (NYSEMKT:PHGE) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.02. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE). Who are BiomX's major shareholders? BiomX's stock is owned by a variety of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (19.59%) and Johnson & Johnson (3.48%). Insiders that own company stock include Assaf Oron, Chidozie Ugwumba, Israel Biofund Gp Limi Orbimed, Jonathan Eitan Solomon, Lynne Marie Sullivan and Marina Wolfson. View institutional ownership trends. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:PHGE) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyThis unknown company solves the biggest issue with AIManward PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryElon’s New A.I. Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist My Default Watchlist Adding BiomX Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
